The paper, titled, Expanding the human gut microbiome atlas of Africa, was published today in Nature, the world’s leading scientific journal.

The gut microbiome has a significant impact on human health, and the lack of knowledge of the diversity of microbiomes in Africa has been a barrier to future health interventions and research. 

The study is a critical development in gut health research globally as much more can now be learned, particularly about diseases such as cancer, diabetes, and obesity, and their relationship to gut microbiota. 

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective approach to developing novel targeted therapies for cancer and other chronic diseases. The MYC family of proteins, which are transcription factors, play a pivotal role in many cellular processes. However, dysregulation of MYC, such as amplification of MYCN, is associated with tumorigenesis, especially for neuroblastoma. MDM2, on the other hand, is one of the most frequently studied oncogenes and is an excellent target for cancer therapy, based on its p53-dependent and p53-independent oncogenic activities in various cancers.